SG11201909689TA - Method and system for monitoring a diabetes treatment plan - Google Patents

Method and system for monitoring a diabetes treatment plan

Info

Publication number
SG11201909689TA
SG11201909689TA SG11201909689TA SG11201909689TA SG 11201909689T A SG11201909689T A SG 11201909689TA SG 11201909689T A SG11201909689T A SG 11201909689TA SG 11201909689T A SG11201909689T A SG 11201909689TA
Authority
SG
Singapore
Prior art keywords
alc
patient
predicted
international
monitoring
Prior art date
Application number
Inventor
Sidney Soong-Ling Chan
Original Assignee
Chan Sidney Soong Ling
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chan Sidney Soong Ling filed Critical Chan Sidney Soong Ling
Publication of SG11201909689TA publication Critical patent/SG11201909689TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235—Details of waveform analysis
    • A61B5/7246—Details of waveform analysis using correlation, e.g. template matching or determination of similarity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7282—Event detection, e.g. detecting unique waveforms indicative of a medical condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/74—Details of notification to user or communication with user or patient ; user input means
    • A61B5/746—Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/06—Buying, selling or leasing transactions
    • G06Q30/0601—Electronic shopping [e-shopping]
    • G06Q30/0631—Item recommendations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

WO 18/ 23 2487 Al -Time Intervals for Ile, Measured A1c — Terse 1115 - Blood Glucose ON• -Model—Formulas and Time Int. 127 to evaluate predicted Plc 125 Apply BFM and adjustment factor to calculate predicted FI G.2 Upload New Measured Alc Upload New Blood Glucose Data Ouput re;cted Alc ' pee. 111 Obtain plurality of BGavE valu„ 1E1 Glucose data 131 Don pred15350 Output predicted alc excestl555551ation and escalelon alert to threshok13 ontli1.5511555 U5 I/155015E5d 5111314:5151 (BM) by selectlng 5155151with lawn ever.\" varlance between cal51.551 AU memund1115 123 Calculate accordingto eFM Determine adjustment factor for BFM (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 December 2018 (27.12.2018) WIP0 I PCT omit VIII °nolo III minim IH mo Imo oimIE (10) International Publication Number WO 2018/232487 Al (51) International Patent Classification: GO6Q 50/22 (2018.01) GOOF 19/00 (2018.01) G16H 20/00 (2018.01) G16H 10/60 (2018.01) A61B 90/00 (2016.01) A61B 5/145 (2006.01) (21) International Application Number: PCT/CA2017/050753 (22) International Filing Date: 20 June 2017 (20.06.2017) (25) Filing Language: English (26) Publication Language: English (72) Inventor; and (71) Applicant: CHAN, Sidney Soong-Ling [CA/SG]; 33-01, 53 Cairnhill Road, Singapore 229664 (SG). (74) Agent: EDWARDS, Antony C.; 400-444 7 Avenue SW, Calgary, Alberta T2P0X8 (CA). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) (54) Title: METHOD AND SYSTEM FOR MONITORING A DIABETES TREATMENT PLAN (57) : A method and system for monitoring the effectiveness of a patient's diabetes treatment plan by predicting, on a frequent basis, the patient's glycated hemoglobin (Alc) based on the patient's blood glucose (BG) may include applying a plurality of Alc models to a BG data set of the patient so as to obtain a plurality of calculated Alc values and identifying a best fit model amongst the plurality of Alc models by evaluating the plurality of calculated Alc values against at least one measured Alc value; calculating a predicted Alc value by applying the identified best fit model to the BG da- ta set. Some embodiments may further include evaluating the predicted Alc value against a set of escalation rules to determine whether an escalation alert is required; alerting the patient's healthcare provider when it is determined the escalation alert is required; and outputting the predicted Alc value to the patient.
SG11201909689T 2017-06-20 2017-06-20 Method and system for monitoring a diabetes treatment plan SG11201909689TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2017/050753 WO2018232487A1 (en) 2017-06-20 2017-06-20 Method and system for monitoring a diabetes treatment plan

Publications (1)

Publication Number Publication Date
SG11201909689TA true SG11201909689TA (en) 2019-11-28

Family

ID=64736237

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909689T SG11201909689TA (en) 2017-06-20 2017-06-20 Method and system for monitoring a diabetes treatment plan

Country Status (6)

Country Link
US (1) US11793471B2 (en)
EP (1) EP3642789A4 (en)
AU (1) AU2017420200A1 (en)
CA (1) CA3064598A1 (en)
SG (1) SG11201909689TA (en)
WO (1) WO2018232487A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022050992A1 (en) * 2020-09-02 2022-03-10 Twin Health, Inc. Virtually monitoring glucose levels in a patient using machine learning and digital twin technology

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI112545B (en) * 1997-05-30 2003-12-15 Nokia Corp Method and system for predicting the level of a glycosylated hemoglobin component in a patient's blood
US6277071B1 (en) 1999-06-25 2001-08-21 Delphi Health Systems, Inc. Chronic disease monitor
US7025425B2 (en) * 2000-03-29 2006-04-11 University Of Virginia Patent Foundation Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data
DE60133653T2 (en) * 2000-08-18 2009-06-04 Animas Technologies Llc APPARATUS FOR PREDICTING HYPOGLYECURE DROPS
US8538703B2 (en) 2002-08-13 2013-09-17 University Of Virginia Patent Foundation Method, system, and computer program product for the processing of self-monitoring blood glucose(SMBG)data to enhance diabetic self-management
US7824333B2 (en) * 2006-03-31 2010-11-02 Lifescan, Inc. Diabetes management methods and systems
US20100145174A1 (en) * 2008-02-12 2010-06-10 Alferness Clifton A System And Method For Providing A Personalized Tool For Estimating Glycated Hemoglobin
US20100198021A1 (en) 2008-02-12 2010-08-05 Alferness Clifton A Computer-implemented method for providing a tunable personalized tool for estimating glycated hemoglobin
US8924159B2 (en) * 2008-05-30 2014-12-30 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US8591410B2 (en) * 2008-05-30 2013-11-26 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US20100330598A1 (en) 2009-06-26 2010-12-30 Roche Diagnostics Operations, Inc. METHOD, SYSTEM, AND COMPUTER PROGRAM PRODUCT FOR PROVIDING BOTH AN ESTIMATED TRUE MEAN BLOOD GLUCOSE VALUE AND ESTIMATED GLYCATED HEMOGLOBIN (HbA1C) VALUE FROM STRUCTURED SPOT MEASUREMENTS OF BLOOD GLUCOSE
US20120253840A1 (en) * 2009-12-21 2012-10-04 Stc.Unm System and methods for estimating hba1c, treatment response, and hypoglycemia risk using self-monitoring of blood glucose data
ES2962508T3 (en) 2011-01-31 2024-03-19 Hoffmann La Roche Visualization of biological values
JP5997453B2 (en) * 2011-04-25 2016-09-28 アークレイ株式会社 Information processing apparatus and user terminal
CA2902042C (en) 2013-02-21 2021-09-07 University Of Virginia Patent Foundation Tracking changes in average glycemia in diabetics
CA3027019C (en) 2015-06-08 2023-10-03 University Of Virginia Patent Foundation System and method for tracking changes in average glycemia in diabetics
AU2016308953B2 (en) 2015-08-20 2020-09-10 Aseko, Inc. Diabetes management therapy advisor

Also Published As

Publication number Publication date
CA3064598A1 (en) 2018-12-27
AU2017420200A1 (en) 2020-01-16
EP3642789A4 (en) 2021-01-27
US11793471B2 (en) 2023-10-24
EP3642789A1 (en) 2020-04-29
WO2018232487A1 (en) 2018-12-27
US20200121257A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
SG11201908288XA (en) Configurable annotations for privacy-sensitive user content
SG11201810221YA (en) Fidelity estimation for quantum computing systems
SG11201408002TA (en) Multi-parameter diabetes risk evaluations
SG11201908088RA (en) Antibodies against pd-l1
SG11201903928WA (en) Mesenchymal stem cells populations, their products, and use thereof
SG11201901834WA (en) Micrornas as biomarkers for endometriosis
SG11201806340YA (en) Zika virus vaccine
SG11201806861SA (en) Combination therapy with anti-cd73 antibodies
SG11201804643PA (en) Indicator device
SG11201909383PA (en) Customizable composite dressings for improved granulation and reduced maceration negative-pressure treatment
SG11201408383SA (en) Methods of detecting diseases or conditions using circulating diseased cells
SG11201407860PA (en) Exendin-4 peptide analogues
SG11201408092UA (en) Endoprosthesis and delivery device for implanting such endoprosthesis
SG11201407292QA (en) Kernel-level security agent
SG11201407459QA (en) System and method for predicting the immunogenicity of a peptide
SG11201807306XA (en) Uniqueness level for anonymized datasets
SG11201901351UA (en) A patient interface, system and method
SG11201408434QA (en) Targeted rna-seq methods and materials for the diagnosis of prostate cancer
SG11201910195WA (en) Methods for trapping and barcoding discrete biological units in hydrogel
SG11201809749VA (en) Computer systems and methods for implementing in-memory data structures
SG11201408037SA (en) Humanized anti-trka antibodies with amino acid substitutions
SG11201407364QA (en) Occlusion detection
SG11201807719SA (en) Use of clinical parameters for the prediction of sirs
SG11201408333UA (en) Bulk purchasing by ad hoc consumer groups
SG11201900123TA (en) Compositions and methods for treating frontotemporal dementia